Enteral topiramate in a pediatric patient with refractory status epilepticus: a case report and review of the literature.

Journal: The Journal Of Pediatric Pharmacology And Therapeutics : JPPT : The Official Journal Of PPAG
Published:
Abstract

We describe the use of topiramate in a healthy 12-year-old (88-kg) male who developed refractory generalized convulsive status epilepticus. Seizures persisted despite aggressive use of benzodiazepines (intravenous lorazepam; oral clorazepate), barbiturates (i.e., phenobarbital, pentobarbital), and hydantoins. The child's seizures were controlled with nasogastrically administered topiramate in doses up to 500 mg twice daily (11.4 mg/kg/day). The patient did not display any clinical or laboratory signs of metabolic acidosis while receiving topiramate. Topiramate should be considered as a treatment option in refractory status epilepticus.

Authors
Chasity Shelton, Elizabeth Alford, Stephanie Storgion, James Wheless, Stephanie Phelps